Kornimate/medical-research-clean huggingface dataset:
integrated cervical cancer screening in mayuge district uganda (aspire mayuge)

Conditions: Human Papillomavirus 16; Human Papillomavirus 18; Papillomavirus Infections; Cervical Cancer; Pre-Cancerous Dysplasia

Summary: the purpose of this pragmatic cluster randomized control trial is to test the effectiveness of cervical cancer screening follow-up completion using two implementation approaches for self-collected hpv testing in a rural, low-resource setting: 1) community health workers recruiting women door-to-door and 2) community health workers recruiting women at community health meetings. this study will also help to further understand how current patient referral systems are working between health facilities, patient and provider preferences for integrated care and health system related barriers to integrated cervical cancer screening. hypothesis: more women will receive screening via the community health meeting but the engagement to care (i.e., visual inspection with acetic acid-our main outcome) will be greater in the door-to-door arm.

a cluster randomized control trial will be conducted with the objective of understanding differences in the effectiveness of cervical cancer screening models using self-collected hpv testing on engagement in care. in 31 villages, women will be recruited for self-collected cervical cancer and sexually transmitted infection (sti) screening by: 1) community health worker recruitment for self-collection (door-to-door), 2) community health meetings. visual inspection with acetic acid (via), cryotherapy and thermocoagulation will be offered in local health facilities for all women who test positive for high-risk (hr)-hpv types. women needing advanced cancer care will be referred to the uganda cancer institute in kampala. the unit of randomization (2 arms) will be villages and the analysis will also account for clustering within this unit or randomization. all participants will receive an integrated package of cervical cancer screening and education and will participate in a survey at baseline. samples will be tested using genexpert (xperthpv) point of care testing at the kigandalo health facility for hpv and high risk hpv (hr-hpv). intervention arms will be implemented in phases by year to avoid temporal contamination.

Eligibility criteria:
inclusion criteria: * women with no previous history of hysterectomy * aged 25-49 years old * no previous history of treatment for cervical cancer * provided written informed consent. exclusion criteria: * women who are under 25 or over 49 years of age, * who have previously had a hysterectomy or been treated for cervical cancer * unable to provided informed consent.

Keywords: human papillomavirus dna tests visual inspection with acetic acid global health developing countries self-collection cervical cancer screening
clinical trial to explore the efficacy and safety of da-4001 after topical application

Conditions: Androgenetic Alopecia

Summary: this study is designed to explore the efficacy and safety of da-4001 after topical application in male patients with androgenetic alopecia design : randomized, double-blind, active-controlled study investigational product : finasteride, minoxidil


Eligibility criteria:
inclusion criteria: * basic and specific(basp) classification : basic type is m2 or c2 and specific type is v1,v2 or f1,f2 exclusion criteria: * evidence of hair loss other than androgenetic alopecia * use of finasteride, dutasteride within previous 12 months * use of minoxidil within previous 6 months * use of androgenic or anti-androgenic agents within previous 6 months * use of steroid agents for local application to scalp or systemic application within previous 1 month * history of hair transplantation, scalp reduction * coronary artery disease, arrhythmia, congestive heart failure, valvular haert disease, angina pectoris
changes in lung aeration and inspiratory effort with and without awake prone

Conditions: Respiratory Distress Syndrome; Ventilation Therapy; Complications

Summary: the investigators aimed to investigate the ventilation homogeneity and transpulmonary pressure during treatments of high-flow nasal cannula(hfnc) and (cpap) on supine and prone position for covid-19 or non-covid-19 patients with acute hypoxemic respiratory failure (ahrf).

awake prone positioning (app) for non-intubated patients has been reported to improve oxygenation for patients with acute hypoxemic respiratory failure (ahrf),particularly for patients with covid-19 induced ahrf, app has been shown to decrease the need of intubation.similarly, app with helmet continuous positive airway pressure (cpap) enables a reduction in the work of breathing and an improvement in oxygenation and sensation of dyspnea in covid-19-associated acute respiratory distress syndrome (ards). moreover, among intubated patients with ards assessed by electro-impedance tomography (eit), prone positioning was found to reduce alveolar overdistention and collapse, resulting in improvement of ventilation homogeneity.however, the effects of app on the ventilation homogeneity and work of breathing for non-covid-19 patients with ahrf remain unknown. high-flow nasal cannula (hfnc) has been proven to improve oxygenation and reduce intubation rate for patients with ahrf in multiple meta-analyses,and has been recommended to treat ahrf in several recently published guidelines.cpap provides consistent level of positive end-expiratory pressure (peep), in comparison to variable level of peep generated by hfnc, thus cpap was reported to have greater improvement of oxygenation than hfnc in 20 patients with ahrf, more importantly, they found that among patients who avoided intubation, the extent of oxygenation improvement was greater with hfnc+app than with niv+app, in contrast, for patients who were intubated, the extent of oxygenation improvement was greater with niv+app than with hfnc+app.this raised the concerns of the self-inflicted lung injury (sili) generated by heterogenous aeration and large swings of transpulmonary pressure. thus, the investigators aimed to investigate the ventilation homogeneity and transpulmonary pressure during treatments of hfnc and cpap on supine and prone.

Eligibility criteria:
inclusion criteria: * adult patients (18-90 years) who have acute hypoxemic respiratory failure, requiring fio2 \> 0.4 to maintain spo2 at 90-95% during hfnc at 50 l/min exclusion criteria: * patients who need immediate intubation; refuse to participate in the study; unable to communicate; have contraindication to place the esophageal catheter; unable to use eit, such as open-chest surgery with chest tube placement; have contraindication for prone positioning, including pregnant, post-abdomen surgery within a week; hypercapnic respiratory failure.
recombinant bnp on heart and renal function in acute heart failure

Conditions: Acute Heart Failure; Acute Renal Failure

Summary: the purpose of this study is to evaluate the efficacy and safety of recombinant human b-type natriuretic peptide (rhbnp) on heart and renal function in patients with acute decompensated heart failure (adhf) and acute renal injury (aki).

patients with acute decompensated heart failure (adhf) and acute renal injury (aki) will be randomized to receive standard of care with or without additional rhbnp. clinical heart function, lvef, scr, gfr and other laboratory parameters will be evaluated.

Eligibility criteria:
inclusion criteria: * acute heart failure with acute renal injury exclusion criteria: * not tolerate to rhbnp

Keywords: recombinant bnp diuretics acute decompensated heart failure acute renal injury heart function renal function
phase i clinical trial of diphtheria, tetanus and acellular pertussis (three components) combined vaccine, adsorbed .

Conditions: Diphtheria; Tetanus; Pertussis

Summary: pertussis, diphtheria and tetanus are seriously infectious diseases in children. since using of the vaccine targeted the three components, it greatly reduced incidence of the three kinds of diseases. the purpose of this study is to preliminary evaluate the safety of dtcp compared to adsorbed diphtheria and tetanus combined vaccine （dt），diphtheria-tetanus-acellular pertussis vaccine（dtap） or pentaxim（dtap-ipv-hib） in participants.

study participants will receive a single booster dose of dtcp or a single booster dose of local dt in 4 to 6 years old ,a singel booster dose of dtcp or a single booster dose of dtap in 18 to 24 months, three basic doses of dtcp or three doses of dtap/ dtap-ipv-hib in 2 to 6 months.safety profile will be assessed in all subjects up to day 30 post vaccination.

Eligibility criteria:
inclusion criteria: * healthy subjects aged 2months、3months、18-24months and 4-6 years old; * willing to provide proof of identity; * able to understand and sign the informed consent by guardians or trustees; * able and willing comply with the requirements of the protocol by guardians or trustees; * subjects of 2 months age have not been vaccinated with diphtheria, ipv, hib, or 13-valent pneumococcal polysaccharide conjugate vaccine; * subjects of 3 months have not been inoculated with vaccines containing diphtheria, hib, 13-valent pneumococcal polysaccharide conjugate vaccine and meningococcal group ac bivalent meningococcal conjugate vaccine;volunteers of 3 months (c3 group) have not been inoculated with vaccines containing ipv; * subjects aged 18-24 months who had completed the immunization program of 3 doses of dtap and had without the fourth dtap vaccine ; * subjects aged 4-6 years who have completed the immunization program of 4 doses of dtap or similar vaccines containing dtp component, but who have not received dt vaccine; exclusion criteria: * premature birth in infant under 1 year of age (delivery before the 37th week of pregnancy)or low birth weight (birth weight\< 2300g for girls,\<2500g for boys); * history of abnormal labor process or asphyxia rescue ; * subjects who has a medical history of diphtheria, pertussis or tetanus; * in the past 30 days, individuals who have had contact with individuals with confirmed pertussis, diphtheria and tetanus diseases in their families; * allergic person; * any prior administration of blood products in last 3 month; * any prior administration of other research medicines in last 1 month; * plans to participate in or is participating in any other drug clinical study; * any prior administration of attenuated live vaccine in last 14 days; * any prior administration of subunit or inactivated vaccines in last 7 days; * had fever before vaccination, subjects with temperature \>37.0°c on axillary setting; * according to the investigator's judgment, the subjects have any other factors that make them unfit to participate in the clinical trial

Keywords: infection dtcp whooping cough vaccine diphtheria tetanus pertussis
centralised pan-algerian survey on the undertreatment of hypercholesterolemia

Conditions: Hypercholesterolemia; Cardiovascular Disease; Hypertension; Diabetes; Coronary Heart Disease; Peripheral Arterial Disease

Summary: centralized pan-algerian survey on the undertreatment of hypercholesterolemia. the purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the ldl-c goals according to the third joint european task force guidelines in the survey population.

centralised pan-algerian survey on the undertreatment of hypercholesterolemia.

Eligibility criteria:
inclusion criteria: * subject must provide informed consent and comply with the survey procedures. * subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. exclusion criteria: - subjects who are unwilling or unable to provide informed consent.

Keywords: hypercholesterolemia cardiovascular disease hypertension coronary heart disease peripheral arterial disease
assessment of quadriceps muscle electrostimulation used in patients suffering from cystic fibrosis

Conditions: Cystic Fibrosis; Mucoviscidosis

Summary: this is an add-on, randomized, open label, clinical trial that evaluates the use of quadriceps electrostimulation as an additional retraining procedure in patients suffering from cystic fibrosis.

cystic fibrosis is an autosomal recessive genetic disease due to a mutation of the cftr protein gene. the cftr protein transports chloride ions (cl-) across cell membranes in the lungs, pancreas, digestive tract, reproductive tract, and skin. cftr mutation mainly leads to a dysfunction of the pulmonary system and pancreas exocrine function. several studies showed that cystic fibrosis commonly induces a reduction of effort tolerance, peripheral muscular strength and work capacity. patients suffering from cystic fibrosis with a high endurance capacity have a lower risk of poor prognosis. those with a severe dyspnea have a higher benefit with a force training or a combined force and endurance training than with endurance training alone. we propose to study the effect of a quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer, in patients with cystic fibrosis associated with severe pulmonary dysfunction, to enhance their muscular performance and increase their adherence to the cycloergometer retraining program. this is a randomized trial with two groups: group a: experimental group, twenty patients. six weeks with electrostimulation program followed by six weeks under a cycloergometer program. group b: control group, twenty patients. six weeks with their usual physical activity followed by six weeks with a cycloergometer program. the randomization is stratified on expiratory volume per second. the size of randomization blocks is random because of the open design.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * patient suffering from cystic fibrosis * patient has at least three measures of maximum expiratory volume per second \<= 45% of the theory among the 6 last measures performed * affiliation to french social security * capacity to consent exclusion criteria: * pregnant women * contraindication to application of magnetic field * pacemaker * history of neurosurgical intervention * presence of metallic particles near the stimulation site.

Keywords: cystic fibrosis mucoviscidosis electrostimulation retraining
decreasing catheter-associated urinary tract infections in the pediatric intensive care unit

Conditions: Urinary Tract Infections

Summary: the purpose of this study is to identify risk factors associated with indwelling urinary catheters, as well as to assess the nurses' knowledge and adherence to hospital policies. the study will also include a very extensive literature search in an attempt to create a national standard or guideline.


Eligibility criteria:
inclusion criteria: 1. medical records of 67 patients 0 to 17 years of age diagnosed with a catheter associated urinary tract infection (defined by cdc) acquired during a picu hospitalization. 2. medical records of 67 patients 0 to 17 years of age who had an indwelling urinary catheter during a picu hospitalization without a catheter associated urinary tract infection. 3. nurses employed at children's mercy hospital in the picu. 4. patient's who acquired a ca-uti during 2009 and was adjudicated by infection control. exclusion criteria: patients 1. patients with community acquired urinary tract infections 2. patients 18 years and older cared for in the picu. 3. patients with catheter associated urinary tract infections hospitalized outside the picu at children's mercy hospital. 4. patients with uti not related to catheterization nurses 1. nurses floated to the picu who are not permanent staff members (icn nurse, float pool staff, travelers) 2. nurses on the research team

Keywords: indwelling urinary catheters urinary tract infections foley-catheter related infections hospital acquired ca-uti
prospective investigation of oxidative stress in west nile virus infection

Conditions: West Nile Virus; West Nile Fever; West Nile Fever Encephalitis; West Nile Fever Meningitis; West Nile Meningitis; West Nile Virus Meningoencephalitis; West Nile Fever Meningoencephalitis; West Nile Fever With Neurologic Manifestation; Oxidative Stress

Summary: the investigator hypothesizes that oxidative stress responses to west nile virus infection in the central nervous system determine the severity of infection and the long-term neurological, neuropsychological and functional sequelae of west nile neuroinvasive disease.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent. if the clinical condition of the patient does not permit giving consent, informed consent will be obtained from the next of kin. * age 18 years or older * for active cases: positive anti-wnv igm antibodies in serum (or igg in csf if applicable) * for active cases: presentation within (maximum) 7days of symptom onset * for healthy controls: anti-wnv antibody naive (igm and igg in serum). the group of healthy controls will be selected to have an age similar distribution to the cases. exclusion criteria: * evidence of active systemic infection in 3 months prior to recruitment * evidence of systemic inflammatory illness * clinical signs of neurodegenerative or neurologic disease other than wnnd * pregnancy * active malignancy * history of drug abuse

Keywords: genome sequencing composite diagnosis
condensed nanofat grafting for treatment of androgenetic alopecia

Conditions: Androgenic Alopecia

Summary: nowadays, multiple treatment modalities have been applied clinically to treat androgenic alopecia, such as follicular unit transplantation(fut), finasteride, platelet-rich plasma injection(prp), etc. in this clinical trial, the investigators aim to analyze the effect of nanofat grafting on treating androgenic alopecia in male.

the investigators will treat the hair loss area of a patient by processed nanofat grafting. the participants were asked to come back 1、3、6、9、12 months after treatment for further follow-up. before and after the treatment, the hair and follicular will be assessed subjectively by satisfaction assessment, dermatoscope.

Eligibility criteria:
inclusion criteria: * male patients with androgenic alopecia aging from 18 to 50. * no scars and wounds on the alopecia area. * no skin disease or serious cardiovascular disease. * preoperative examinations remain healthy. exclusion criteria: * serious chronic heart, liver, kidney, blood system disease * allergic diseases, skin inflammation or wounds * alopecia but not androgenic alopecia * acute or chronic infection * take anticoagulant drugs * active vitiligo, psoriasis, systemic lupus erythematosus

Keywords: nanofat hair loss prp
inspired: smartphone videogame-based smoking cessation intervention

Conditions: Smoking Cessation

Summary: the investigators are testing a new, smartphone videogame-based intervention for smoking cessation.

the investigators have developed a novel smartphone videogame, where smokers are required to submit breath carbon monoxide samples to demonstrate smoking abstinence, and where they will earn game-based rewards contingent on meeting co goals. players will be working with teams to earn group and social rewards to help advance their game.

Eligibility criteria:
inclusion criteria: * inclusionary criteria: participants will be required to be of legal smoking age (\>19 in alabama, alaska, new jersey, utah, and in onondaga, nassau and suffolk counties in new york, \> 18 years of age in the remainder of the united states). participants must also report smoking \>10 cigarettes per day, report smoking for \>2 years, answer 8 or higher on a likert scale asking how much the person wishes to quit smoking right now (1 = not at all, 10 =very much), have a smartphone with a data plan and active contract extending for at least two months from the enrollment date (i.e., the duration of the study), and reside in the u.s. participants in the study must submit an initial co reading \> 10ppm (to prevent nonsmokers from enrolling in the study), literacy will be assessed by having the participant read the first few lines of the consent form out loud, and will be an inclusion criterion because elements of "breathe free" will require reading. exclusion criteria: * individuals will be excluded from the study if they report smoking any combustible products \>2 times per month, report unstable medical/psychiatric conditions that might interfere with the study objectives (e.g., asthma), report living with someone who smokes in the house, or has a career that results in excessive exposure to co. all excluded participants will be emailed the following smoking cessation information: the "clearing the air" packet developed by the national cancer institute, smokefree.gov, quitsmokinghelpline.com, and the national academies press "dying to quit."
a follow-up study to evaluate the safety of allo-asc-dfu in allo-asc-dfu-301 clinical trial

Conditions: Diabetic Foot Ulcer

Summary: this is a follow-up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 3 clinical trial (allo-asc-dfu-301) for 24 months

this is an open-label follow up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 3 clinical trial (allo-asc-dfu-301) for 24 months. allo-asc-dfu is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (vegf) and hepatocyte growth factor (hgf), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a diabetic foot ulcer.

Eligibility criteria:
inclusion criteria: 1. subjects who are treated with allo-asc-dfu sheet or vehicle sheet in phase 3 clinical trial of allo-asc-dfu-301. 2. subjects who are able to give written informed consent prior to study start and to comply with the study requirements. exclusion criteria: 1. subjects who are considered not suitable for the study by the principal investigator.
d-lung: an analytics platform for lung cancer based on deep learning technology

Conditions: Lung Cancer

Summary: lung cancer is one of main cause of cancer death in worldwide, characterized of low 5-year survival rate of less than 20%. pulmonary nodule is considered as the typical imaging manifestation in early stage of lung cancer. the national lung screen trial has demonstrated that the mortality rates could decline greatly, by the utility of low-dose helical computed tomography for screen of pulmonary nodules. thus, automatic detection, diagnosis and management of pulmonary nodules, play the vital roles in computer-aided lung cancer screening and early intervention.


Eligibility criteria:
inclusion criteria: * subjects with suspicious lung nodules. * thin-layer thoracic ct and pathology examination have been performed for suspicious lung nodules. exclusion criteria: * subjects with accompanied lesions on ct images that may interfere to lung nodules analysis

Keywords: lung nodules deep learning